Journal
JOURNAL OF NUCLEAR MEDICINE
Volume 63, Issue 12, Pages 1802-1808Publisher
SOC NUCLEAR MEDICINE INC
DOI: 10.2967/jnumed.122.263895
Keywords
molecular imaging; oncology; nanodiagnostics; nanome-dicine; nanoparticles; theranostics
Funding
- Excellence Strategy of the Federal Government and the Lander
- European Research Council (ERC COG Meta-Targeting) [864121]
- German Federal Ministry of Research and Education (BMBF) [16GW0319K]
- German Research Foundation (DFG) [GRK2375 [331065168], LA2937/4-1, SFB1066]
- European Research Council (ERC) [864121] Funding Source: European Research Council (ERC)
Ask authors/readers for more resources
This article provides an overview of currently used and evaluated nanoparticle-based imaging agents in the clinic and discusses preclinical progress and translational avenues for the use of nanoparticles in diagnostic and theranostic applications.
Nanoparticles possess unique features that may be useful for disease diagnosis and therapy. Preclinically, many different nanodiagnostics have been explored, but only a few have made it to the market. We here provide an overview of nanoparticle-based imaging agents cur-rently used and evaluated in the clinic and discuss preclinical progress and translational avenues for the use of nanoparticles for diagnostic and theranostic applications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
